| Dr Robert Scott Crandall, MD | |
|
100 Hitchcock Way, Manchester, NH 03104-4125 | |
| (603) 695-2500 | |
| (603) 695-2919 |
| Full Name | Dr Robert Scott Crandall |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 42 Years |
| Location | 100 Hitchcock Way, Manchester, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790794345 | NPI | - | NPPES |
| 30003054 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 8073 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
With health care reform efforts ramping up after the summer break, many of the nation's employers are focusing on the action in Congress and plan to adjust their benefit strategies based on how final legislation affects their costs, according to a survey of 433 HR and benefit executives from midsize and large organizations conducted by professional services firm Towers Perrin.
Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product. This product, which uses Archimedes' proprietary ChiSys® delivery technology, is being developed as a rapidly acting, well tolerated and convenient treatment for chemotherapy-induced nausea and vomiting (CINV).
Participants in two weight-loss programs - one involving traditional health club sessions and the other delivered online in a 3D virtual world - lost similar amounts of weight and body fat, but the online contingent reported significantly greater gains in behaviors that could help them live healthier and leaner lives.
The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 2 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386697803 PECOS PAC ID: 4183537509 Enrollment ID: O20031111000313 |
News Archive
With health care reform efforts ramping up after the summer break, many of the nation's employers are focusing on the action in Congress and plan to adjust their benefit strategies based on how final legislation affects their costs, according to a survey of 433 HR and benefit executives from midsize and large organizations conducted by professional services firm Towers Perrin.
Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product. This product, which uses Archimedes' proprietary ChiSys® delivery technology, is being developed as a rapidly acting, well tolerated and convenient treatment for chemotherapy-induced nausea and vomiting (CINV).
Participants in two weight-loss programs - one involving traditional health club sessions and the other delivered online in a 3D virtual world - lost similar amounts of weight and body fat, but the online contingent reported significantly greater gains in behaviors that could help them live healthier and leaner lives.
The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 2 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
With health care reform efforts ramping up after the summer break, many of the nation's employers are focusing on the action in Congress and plan to adjust their benefit strategies based on how final legislation affects their costs, according to a survey of 433 HR and benefit executives from midsize and large organizations conducted by professional services firm Towers Perrin.
Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product. This product, which uses Archimedes' proprietary ChiSys® delivery technology, is being developed as a rapidly acting, well tolerated and convenient treatment for chemotherapy-induced nausea and vomiting (CINV).
Participants in two weight-loss programs - one involving traditional health club sessions and the other delivered online in a 3D virtual world - lost similar amounts of weight and body fat, but the online contingent reported significantly greater gains in behaviors that could help them live healthier and leaner lives.
The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 2 days ago
| Entity Name | Catholic Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427154335 PECOS PAC ID: 6103897129 Enrollment ID: O20040803001720 |
News Archive
With health care reform efforts ramping up after the summer break, many of the nation's employers are focusing on the action in Congress and plan to adjust their benefit strategies based on how final legislation affects their costs, according to a survey of 433 HR and benefit executives from midsize and large organizations conducted by professional services firm Towers Perrin.
Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product. This product, which uses Archimedes' proprietary ChiSys® delivery technology, is being developed as a rapidly acting, well tolerated and convenient treatment for chemotherapy-induced nausea and vomiting (CINV).
Participants in two weight-loss programs - one involving traditional health club sessions and the other delivered online in a 3D virtual world - lost similar amounts of weight and body fat, but the online contingent reported significantly greater gains in behaviors that could help them live healthier and leaner lives.
The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 2 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
With health care reform efforts ramping up after the summer break, many of the nation's employers are focusing on the action in Congress and plan to adjust their benefit strategies based on how final legislation affects their costs, according to a survey of 433 HR and benefit executives from midsize and large organizations conducted by professional services firm Towers Perrin.
Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product. This product, which uses Archimedes' proprietary ChiSys® delivery technology, is being developed as a rapidly acting, well tolerated and convenient treatment for chemotherapy-induced nausea and vomiting (CINV).
Participants in two weight-loss programs - one involving traditional health club sessions and the other delivered online in a 3D virtual world - lost similar amounts of weight and body fat, but the online contingent reported significantly greater gains in behaviors that could help them live healthier and leaner lives.
The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Scott Crandall, MD 100 Hitchcock Way, Manchester, NH 03104-4125 Ph: (603) 695-2500 | Dr Robert Scott Crandall, MD 100 Hitchcock Way, Manchester, NH 03104-4125 Ph: (603) 695-2500 |
News Archive
With health care reform efforts ramping up after the summer break, many of the nation's employers are focusing on the action in Congress and plan to adjust their benefit strategies based on how final legislation affects their costs, according to a survey of 433 HR and benefit executives from midsize and large organizations conducted by professional services firm Towers Perrin.
Almac Discovery today announced the start of Phase I clinical trial of the novel intranasal Granisetron product. This product, which uses Archimedes' proprietary ChiSys® delivery technology, is being developed as a rapidly acting, well tolerated and convenient treatment for chemotherapy-induced nausea and vomiting (CINV).
Participants in two weight-loss programs - one involving traditional health club sessions and the other delivered online in a 3D virtual world - lost similar amounts of weight and body fat, but the online contingent reported significantly greater gains in behaviors that could help them live healthier and leaner lives.
The U.S. Food and Drug Administration (FDA) in a statement yesterday reported its approval for a new drug, Idhifa (enasidenib) for the treatment of acute myeloid leukemia (AML) in adults that has either relapsed or is refractory to standard chemotherapy.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced positive top-line results from Category 1 abuse-deterrent studies for Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 2 days ago
Dr. Mary Jo Montanarella, M.D Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 30 Canton St, Suite 6, Manchester, NH 03103 Phone: 603-624-1638 Fax: 603-624-1972 | |
Damian Olsen, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 88 Mcgregor St Ste 201, Manchester, NH 03102 Phone: 603-314-7595 | |
Dr. Gary A Wasserman, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 150 Tarrytown Rd, Manchester, NH 03103 Phone: 603-622-3162 Fax: 603-622-8677 | |
Dr. Shirley V Galucki, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2500 | |
Melissa Culverwell, ARNP Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 150 Tarrytown Rd, Manchester, NH 03103 Phone: 603-622-3162 Fax: 603-622-8677 | |
Dr. Erron Laskin Kinsler, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 100 Hitchcock Way, Manchester, NH 03104 Phone: 603-695-2900 Fax: 603-695-2919 | |
Dr. Jennifer M. Donofrio, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 150 Tarrytown Rd, Manchester, NH 03103 Phone: 603-622-3162 Fax: 603-622-8677 |